ArticleCureus2026
Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy With Subsequent Diagnosis of Mantle Cell Lymphoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) immune-mediated necrotizing myopathy (IMNM) is a subtype of autoimmune necrotizing myopathy that presents with progressive proximal weakness and persistent creatine kinase (CK) elevation, which may continue despite statin discontinuation. Its relationship with hematologic malignancy is not well established. A 67-year-old woman developed markedly elevated CK levels after starting high-intensity statin. Despite statin withdrawal, CK levels remain persistently elevated, accompanied by progressive symmetrical proximal weakness. Anti-HMGCR IgG was strongly positive, while other autoimmune serologies were unrevealing. A diagnosis of statin-associated anti-HMGCR IMNM was established, and treatment with mycophenolate mofetil and intravenous immunoglobulin resulted in partial biochemical improvement. Five weeks after initiation of immunosuppressive therapy, routine laboratory testing showed rapidly rising leukocytosis. Further evaluation revealed mantle cell lymphoma with bone marrow involvement, IGH::CCND1 rearrangement, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.